jordixiol.bsky.social - Profile | ThreadSky | a Reddit-style client for Bluesky

Dry powder for European biotech: Sofinnova Partners raises €1.2B to fuel the next wave of life sciences innovation sofinnovapartners.com/news/sofinno...

submitted 2 hours ago • 0 comments

"Coalition of the willing" is the new way Europe needs to operate on everything, not just geopolitics. Just get together the countries who agree on something, and get it done www.theguardian.com/world/2025/m...

submitted 1 day ago • 0 comments

Are European labs seeing an uptick in high-quality postdoc applications? Just curious

submitted 3 days ago • 0 comments

Stem cell therapy in epilepsy: an interview with Jonathon Parker, investigator in Neurona Therapeutic’s pioneering trial #portfolio www.neurologylive.com/view/stem-ce...

submitted 4 days ago • 0 comments

Are low-resolution images in a corporate deck a red flag? yes/no

submitted 4 days ago • 1 comment

John Stewart slices his hand while talking drug pricing The biopharma sector needs to fight the common misconception that drug development is funded by taxpayer money. Basic research and development are both equally necessary, but they're very different things www.dailykos.com/stories/2025...

submitted 6 days ago • 0 comments

First RIPTAC dosed in humans! #RIPTACs #prostatecancer haldatx.com/halda-therap...

submitted 6 days ago • 2 comments

#PortfolioNews | Our #portfolio company Neurona Therapeutics plans Phase3 trial in H2 2025 for NRTX-1001, a #celltherapy for drug-resistant #epilepsy. 🔬 Encouraging early data: Up to 97% seizure reduction with no cognitive impairment 📢 Read more: https://buff.ly/3Dh9kfv #VC

submitted 7 days ago • 0 comments

An overwhelming majority are listed in the US. The time is right for Europe to move towards a common listing

submitted 12 days ago • 1 comment

This is certainly not the first time big pharma finds fraudulent data after they acquire a drug from a biotech company. But it may be one of the first times where they openly admit it Novo Nordisk alleges fraud after $1.3B deal to buy drug from KBP Biosciences www.reuters.com/business/hea...

submitted 13 days ago • 0 comments

Why I Am taking My HAE Cure Idea to My Grave: rnaitherapeutics.blogspot.com/2025/02/why-... $NTLA $BCRX #HAE $KALV $PHVS I may have to change to a different platform, blogger/blogspot is becoming shockingly outdated.

submitted 19 days ago • 1 comment

$AZN key 2025 catalysts. AVANZAR trial (Dato-Dxd + durvalumab + chemo) in first-line lung cancer one to watch The combo of ADC + checkpoint inhibitor worked remarkably well in bladder cancer, will this become a broader concept in oncology treatment?

submitted 25 days ago • 0 comments

🎙️Nueva entrega de nuestro #Podcast! PÍLDORAS DE BIOTECH💊 🎯 𝗝.𝗣. 𝗠𝗼𝗿𝗴𝗮𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 📈 Descubre los acuerdos, #tendencias y #retos que marcarán el 2025 en #pharma y #biotech. ▶️ https://buff.ly/3Q5lgnn #YsiosPodcast #BiotechPillsWithJordi

submitted 26 days ago • 0 comments

$NVS cardiovascular franchise showing its muscle: Both Entresto and Leqvio were characterized as very poor launches, now they are both major growth drivers www.novartis.com/sites/novart...

submitted 31 days ago • 0 comments

#entrevista I🔬#TelescopeBiotechFund , una apuesta estratégica por la #biotecnología cotizada. Descúbrelo con @jordixiol.bsky.social , Partner en @ysioscapital.bsky.social y Horacio Encabo de Andbank en @capitalradiob.bsky.social ▶️ https://buff.ly/3CkLQG7 #FondosDeInversión #MercadoFinanciero

submitted 32 days ago • 0 comments

When Warp Drive Bio first launched I remember thinking those people were insane. Never going to work. Now I’m blown away by every piece of new data with $RVMD’s tri-complex inhibitors. The zeal of the convert

submitted 36 days ago • 0 comments

Efficacy of pan-RAS and KRAS G12D inhibitors from $RVMD in 2L PDAC: 36% and 30% ORR for daraxonrasib and zoldonrasib, respectively #ASCOGI

submitted 36 days ago • 1 comment

Good amycretin data. It looks like it will be able to break the 25% weight loss psychological barrier. The one cagrisema missed and sent Novo down 30%

submitted 38 days ago • 0 comments

One more ADC deal with China: Arrivent licenses ADC from Lepu Biopharma for the treatment of colorectal, pancreatic and other GI cancers. Target undisclosed, $47M in near-term payments $AVBP ir.arrivent.com/news-release...

submitted 40 days ago • 1 comment

Scientist at a not-to-be-named Nasdaq cell therapy company: "I don't know if we're stupid or visionary"

submitted 41 days ago • 0 comments

De novo protein design is the low-hanging fruit of AI for drug discovery www.nature.com/articles/s41...

submitted 47 days ago • 0 comments

$RLAY is going after the same target than Scorpion and has treated many more patients Why is $RLAY trading under cash while Scorpion is getting acquired for up to $2.5B? The value of showing single-agent activity in oncology

submitted 49 days ago • 0 comments

$GILD paying $250M upfront for LEO Pharma’s preclinical STAT6 portfolio. Talk about a hot target #JPM25 www.businesswire.com/news/home/20...

submitted 50 days ago • 0 comments

100 years of quantum mechanics. It remains the most fundamental model for how the universe works, but it still cannot explain gravity, space and time www.nature.com/articles/d41...

submitted 52 days ago • 0 comments

The world’s 280 million electric bikes and mopeds are cutting demand for oil 4x more than electric cars due to their staggering uptake in China and elsewhere.

submitted 92 days ago • 49 comments

One of my contacts has a theory on why the JPM meeting in San Fran is so conducive to deal making: Jetlag + cocktails.

submitted 54 days ago • 1 comment

Amivantamab + lazertinib showed survival benefit over osimertinib in 1L NSCLC with classical EGFR mutations www.targetedonc.com/view/amivant... Meanwhile sunvozertinib, an amivantamab contender in exon20 EGFR-mutated NSCLC, was granted priority review by the FDA www.onclive.com/view/sunvoze...

submitted 55 days ago • 0 comments

X is being used as a political weapon against a democratically elected government in the UK. You all really need to stop posting over there

submitted 58 days ago • 0 comments

Some me-toos and some long shots, but two stand out: - $NVS $IONS Pelacarsen cardiovascular outcomes trial. Lp(a) has been associated with CV disease since the 1970s. First of a highly anticipated class of medicines - MORF-057 Ph2b in UC. Is $LLY on a roll also in BD and can orals replace biologics

submitted 59 days ago • 0 comments

A pretty good year for drug approvals in 2024 www.nature.com/articles/d41... but neurology lags behind recent trends for the year. Top of the list on what to look forward to in 2025 is Suzetrigine (VX-548) for acute (post surgical) pain in Jan!

submitted 60 days ago • 1 comment

What a way to start 2025! Our spliceosome blueprint has been recognized by @forbes.com as one of the “Top Five Breakthroughs of 2024”. Huge thanks to my colleagues and my mentor Juan Valcarcel at @crg.eu #Biotech #Spliceosome #RNA #Innovation www.forbes.com/sites/alexkn...

submitted 61 days ago • 0 comments

The founder of Christianity, a distinct religion from Judaism centered around the divinity of Jesus, was Paul the Apostle, not Jesus himself. Hyam Maccoby is the author that best encapsulates this notion

submitted 64 days ago • 0 comments

🎙️ Highlights de 2024 en Píldoras de Biotech: • Un resultado + un nuevo fármaco + una polémica Y algunas pinceladas para 2025 $SRRK $KRTX $BMY $PFE Escúchalo aquí 👇 open.spotify.com/episode/2ZvF...

submitted 70 days ago • 0 comments

Crazy stat

submitted 73 days ago • 0 comments

Novo Nordisk misses the mark in key obesity Phase 3 trial: Cagrisema showed a 20.4% weight loss at 68 weeks compared to 2.4% for placebo, but expectations were at 25% to clearly differentiate from the 20.9% shown by Tirzepatide $NVO $LLY www.novonordisk.com/content/nnco...

submitted 73 days ago • 1 comment

📢Nos alegra anunciar el lanzamiento de 𝗧𝗲𝗹𝗲𝘀𝗰𝗼𝗽𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗙𝘂𝗻𝗱, gestionado por Andbank , que contará con nuestro asesoramiento especializado. 🎯Fondo con vocación global que invertirá en compañías cotizadas del sector biomédico, principalmente en #Nasdaq y #NYSE 👉 bit.ly/3ZXE8ue #fund

submitted 75 days ago • 0 comments

CRL for subcutaneous Rybrevant due to issues with manufacturing. Another setback for $JNJ in their bid to capture some of the first-line EGFR mutant lung cancer www.biospace.com/fda/j-js-fda...

submitted 76 days ago • 0 comments

The Krebs cycle is not the most important metabolic pathway in biology. The Krebs cycle IS biology

submitted 78 days ago • 0 comments

One big readout remaining for 2024: Cagrisema's Phase 3 trial in obesity After tirzepatide beat semaglutide in a head-to-head with 20% vs. 14% weight loss, Novo needs a convincing result even if it's a cross-trial comparison. They are targeting 25% as the psychological barrier to cross $NVO $LLY

submitted 81 days ago • 0 comments